Vidac Pharma, a Jerusalem, Israel-based clinical stage innovative biopharmaceutical company, raised $9M in Series A financing.
The Israel Biotech Fund made the investment.
Led by Oren M. Becker, Ph.D., president and chief executive officer, and Prof. Max Herzberg, founder and chairman of the board, Vidac Pharma is dedicated to discovering and developing medicines to help people suffering from a range of oncologic and oncodermatologic diseases. The company’s lead product is VDA-1102, a selective VDAC/HK2 modulator formulated as a topical ointment.
The company plans to use the proceeds to advance the development of its lead product, VDA-1102 ointment, which is in Phase 2 clinical trial in patients with actinic keratosis, one of the most common dermatologic conditions worldwide.